<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">38113020</PMID><DateCompleted><Year>2024</Year><Month>01</Month><Day>26</Day></DateCompleted><DateRevised><Year>2024</Year><Month>03</Month><Day>07</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1439-0973</ISSN><JournalIssue CitedMedium="Internet"><Volume>52</Volume><Issue>1</Issue><PubDate><Year>2024</Year><Month>Feb</Month></PubDate></JournalIssue><Title>Infection</Title><ISOAbbreviation>Infection</ISOAbbreviation></Journal><ArticleTitle>Is antiviral treatment at the acute phase of COVID-19 effective for decreasing the risk of long-COVID? A systematic review.</ArticleTitle><Pagination><StartPage>43</StartPage><EndPage>58</EndPage><MedlinePgn>43-58</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s15010-023-02154-0</ELocationID><Abstract><AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">Preliminary evidence suggests a potential effect of antiviral medication used during the acute COVID-19 phase for preventing long-COVID. This review investigates if having received pharmacological treatment during acute SARS-CoV-2 infection may reduce the risk of long-COVID.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">MEDLINE, CINAHL, PubMed, EMBASE, Web of Science databases, as well as medRxiv/bioRxiv preprint servers were searched up to July 15th, 2023. Articles comparing the presence of long-COVID symptoms between individuals who received or not a specific medication, particularly antivirals, during the acute phase of SARS-CoV-2 infection were included. Methodological quality was assessed using the Newcastle-Ottawa Scale or Cochrane's Risk of Bias (Rob) tool.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">From 517 studies identified, 6 peer-reviewed studies and one preprint met all inclusion criteria. The sample included 2683 (n&#x2009;=&#x2009;4) hospitalized COVID-19 survivors and 307,409 (n&#x2009;=&#x2009;3) non-hospitalized patients. The methodological quality was high in 71% of studies (n&#x2009;=&#x2009;5/7). Two studies investigating the effects of Nirmaltrevir/Ritonavir and three studies the effect of Remdesivir reported conflicting results on effectiveness for preventing long-COVID. Three studies investigating the effects of other medication such as Dexamethasone (n&#x2009;=&#x2009;2) or Metformin (n&#x2009;=&#x2009;1) found positive results of these medications for preventing long-COVID.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Available evidence about the effect of medication treatment with antivirals during acute COVID-19 and reduced risk of developing long-COVID is conflicting. Heterogeneous evidence suggests that Remdesivir or Nirmaltrevir/Ritonavir could have a potential protective effect for long-COVID. A limited number of studies demonstrated a potential benefit of other medications such as Dexamethasone or Metformin, but more studies are needed.</AbstractText><CopyrightInformation>&#xa9; 2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Fern&#xe1;ndez-de-Las-Pe&#xf1;as</LastName><ForeName>C&#xe9;sar</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Physical Therapy, Occupational Therapy, Physical Medicine and Rehabilitation, Facultad de Ciencias de la Salud, Universidad Rey Juan Carlos (URJC), Universidad Rey Juan Carlos, Avenida de Atenas S/N, 28922, Alcorc&#xf3;n, Madrid, Spain. cesar.fernandez@urjc.es.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Torres-Macho</LastName><ForeName>Juan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Hospital Universitario Infanta Leonor-Virgen de La Torre, Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medicine, School of Medicine, Universidad Complutense de Madrid, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Catahay</LastName><ForeName>Jesus Alfonso</ForeName><Initials>JA</Initials><AffiliationInfo><Affiliation>Department of Medicine, Saint Peter's University Hospital, New Brunswick, NJ, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Macasaet</LastName><ForeName>Raymart</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Medicine, Monmouth Medical Center, Long Branch, NJ, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Velasco</LastName><ForeName>Jacqueline Veronica</ForeName><Initials>JV</Initials><AffiliationInfo><Affiliation>Faculty of Medicine and Surgery, University of Santo Tomas, Manila, Philippines.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Macapagal</LastName><ForeName>Sharina</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Medicine, John A. Burns School of Medicine, University of Hawaii, Honolulu, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Caldararo</LastName><ForeName>Mario</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Medicine, Saint Peter's University Hospital, New Brunswick, NJ, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Henry</LastName><ForeName>Brandon Michael</ForeName><Initials>BM</Initials><AffiliationInfo><Affiliation>Clinical Laboratory, Division of Nephrology and Hypertension, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lippi</LastName><ForeName>Giuseppe</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Section of Clinical Biochemistry, Department of Neuroscience, Biomedicine and Movement, University of Verona, Verona, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Franco-Moreno</LastName><ForeName>Ana</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Hospital Universitario Infanta Leonor-Virgen de La Torre, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Notarte</LastName><ForeName>Kin Israel</ForeName><Initials>KI</Initials><AffiliationInfo><Affiliation>Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D000078182">Systematic Review</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>12</Month><Day>19</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Infection</MedlineTA><NlmUniqueID>0365307</NlmUniqueID><ISSNLinking>0300-8126</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>O3J8G9O825</RegistryNumber><NameOfSubstance UI="D019438">Ritonavir</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>7S5I7G3JQL</RegistryNumber><NameOfSubstance UI="D003907">Dexamethasone</NameOfSubstance></Chemical><Chemical><RegistryNumber>9100L32L2N</RegistryNumber><NameOfSubstance UI="D008687">Metformin</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="ErratumIn"><RefSource>Infection. 2024 Oct;52(5):1687. doi: 10.1007/s15010-024-02208-x</RefSource><PMID Version="1">38451416</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019438" MajorTopicYN="N">Ritonavir</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003907" MajorTopicYN="N">Dexamethasone</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008687" MajorTopicYN="Y">Metformin</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Antiviral</Keyword><Keyword MajorTopicYN="N">Long-COVID</Keyword><Keyword MajorTopicYN="N">Nirmaltrevir/Ritonavir</Keyword><Keyword MajorTopicYN="N">Post-COVID-19</Keyword><Keyword MajorTopicYN="N">Remdesivir</Keyword><Keyword MajorTopicYN="N">Review</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>11</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>12</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>1</Month><Day>26</Day><Hour>6</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>12</Month><Day>19</Day><Hour>19</Hour><Minute>51</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>12</Month><Day>19</Day><Hour>11</Hour><Minute>26</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38113020</ArticleId><ArticleId IdType="doi">10.1007/s15010-023-02154-0</ArticleId><ArticleId IdType="pii">10.1007/s15010-023-02154-0</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Kim MS, An MH, Kim WJ, Hwang TH. Comparative efficacy and safety of pharmacological interventions for the treatment of COVID-19: a systematic review and network meta-analysis. PLoS Med. 2020;17: e1003501.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pmed.1003501</ArticleId><ArticleId IdType="pubmed">33378357</ArticleId><ArticleId IdType="pmc">7794037</ArticleId></ArticleIdList></Reference><Reference><Citation>Rahmah L, Abarikwu SO, Arero AG, Essouma M, Jibril AT, Fal A, Flisiak R, Makuku R, Marquez L, Mohamed K, Ndow L, Zar&#x119;bska-Michaluk D, Rezaei N, Rzymski P. Oral antiviral treatments for COVID-19: opportunities and challenges. Pharmacol Rep. 2022;74:1255&#x2013;78.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s43440-022-00388-7</ArticleId><ArticleId IdType="pubmed">35871712</ArticleId><ArticleId IdType="pmc">9309032</ArticleId></ArticleIdList></Reference><Reference><Citation>https://www.who.int/emergencies/diseases/novel-coronavirus-2019 (Accessed 15 July 2023)</Citation></Reference><Reference><Citation>Tian F, Chen Z, Feng Q. Nirmatrelvir-ritonavir compared with other antiviral drugs for the treatment of COVID-19 patients: a systematic review and meta-analysis. J Med Virol. 2023;95: e28732.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.28732</ArticleId><ArticleId IdType="pubmed">37183808</ArticleId></ArticleIdList></Reference><Reference><Citation>Hammond J, Leister-Tebbe H, Gardner A, Abreu P, Bao W, Wisemandle W, Baniecki M, Hendrick VM, Damle B, Sim&#xf3;n-Campos A, Pypstra R, Rusnak JM, EPIC-HR Investigators. Oral nirmatrelvir for high-risk, non-hospitalized adults with COVID-19. N Engl J Med. 2022;386:1397&#x2013;408.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2118542</ArticleId><ArticleId IdType="pubmed">35172054</ArticleId></ArticleIdList></Reference><Reference><Citation>Amstutz A, Speich B, Mentr&#xe9; F, et al. Effects of remdesivir in patients hospitalised with COVID-19: a systematic review and individual patient data meta-analysis of randomised controlled trials. Lancet Respir Med. 2023;11:453&#x2013;64.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-2600(22)00528-8</ArticleId><ArticleId IdType="pubmed">36828006</ArticleId><ArticleId IdType="pmc">10156140</ArticleId></ArticleIdList></Reference><Reference><Citation>Gottlieb RL, Vaca CE, Paredes R, Mera J, Webb BJ, Perez G, Oguchi G, Ryan P, Nielsen BU, Brown M, Hidalgo A, Sachdeva Y, Mittal S, Osiyemi O, Skarbinski J, Juneja K, Hyland RH, Osinusi A, Chen S, Camus G, Abdelghany M, Davies S, Behenna-Renton N, Duff F, Marty FM, Katz MJ, Ginde AA, Brown SM, Schiffer JT, Hill JA, GS-US-540-9012 (PINETREE) Investigators. Early remdesivir to prevent progression to severe COVID-19 in outpatients. N Engl J Med. 2022;386:305&#x2013;15.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2116846</ArticleId><ArticleId IdType="pubmed">34937145</ArticleId></ArticleIdList></Reference><Reference><Citation>Wen W, Chen C, Tang J, Wang C, Zhou M, Cheng Y, Zhou X, Wu Q, Zhang X, Feng Z, Wang M, Mao Q. Efficacy and safety of three new oral antiviral treatment (molnupiravir, fluvoxamine and paxlovid) for COVID-19: a meta-analysis. Ann Med. 2022;54:516&#x2013;23.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/07853890.2022.2034936</ArticleId><ArticleId IdType="pubmed">35118917</ArticleId><ArticleId IdType="pmc">8820829</ArticleId></ArticleIdList></Reference><Reference><Citation>Zadeh F, Wilson D, Agrawal D. Long COVID: complications, underlying mechanisms, and treatment strategies. Arch Microbiol Immunol. 2023;7:36&#x2013;61.</Citation><ArticleIdList><ArticleId IdType="pubmed">37388279</ArticleId><ArticleId IdType="pmc">10310313</ArticleId></ArticleIdList></Reference><Reference><Citation>Fern&#xe1;ndez-de-las-Pe&#xf1;as C. Long COVID: current definition. Infection. 2022;50:285&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s15010-021-01696-5</ArticleId><ArticleId IdType="pubmed">34519974</ArticleId></ArticleIdList></Reference><Reference><Citation>Soriano JB, Murthy S, Marshall JC, Relan P, Diaz JV, WHO Clinical Case Definition Working Group on Post-COVID-19 Condition. A clinical case definition of post-COVID-19 condition by a Delphi consensus. Lancet Infect Dis. 2022;22:e102&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(21)00703-9</ArticleId><ArticleId IdType="pubmed">34951953</ArticleId></ArticleIdList></Reference><Reference><Citation>Global Burden of Disease Long COVID Collaborators, Wulf Hanson S, Abbafati C, et al. Estimated global proportions of individuals with persistent fatigue, cognitive, and respiratory symptom clusters following symptomatic COVID-19&#xa0;in 2020 and 2021. JAMA. 2022;328:1604&#x2013;15.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2022.18931</ArticleId><ArticleId IdType="pmc">9552043</ArticleId></ArticleIdList></Reference><Reference><Citation>Rahmati M, Udeh R, Yon DK, Lee SW, Dolja-Gore X, McEVoy M, Kenna T, Jacob L, L&#xf3;pez S&#xe1;nchez GF, Koyanagi A, Shin JI, Smith L. A systematic review and meta-analysis of long-term sequelae of COVID-19 2-year after SARS-CoV-2 infection: a call to action for neurological, physical, and psychological sciences. J Med Virol. 2023;95: e28852.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.28852</ArticleId><ArticleId IdType="pubmed">37288652</ArticleId></ArticleIdList></Reference><Reference><Citation>Suran M. VA Finds nirmatrelvir associated with lower risk of long COVID. JAMA. 2022;328:2386.</Citation><ArticleIdList><ArticleId IdType="pubmed">36573991</ArticleId></ArticleIdList></Reference><Reference><Citation>Peluso MJ, Anglin K, Durstenfeld MS, et al. Effect of oral nirmatrelvir on long COVID symptoms: 4 cases and rationale for systematic studies. Pathog Immun. 2022;7:95&#x2013;103.</Citation><ArticleIdList><ArticleId IdType="pubmed">35800257</ArticleId><ArticleId IdType="pmc">9254867</ArticleId></ArticleIdList></Reference><Reference><Citation>Seb&#x151;k S, Gyires K. Long&#xa0;COVID&#xa0;and possible preventive options. Inflammopharmacology. 2023. https://doi.org/10.1007/s10787-023-01204-1 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10787-023-01204-1</ArticleId><ArticleId IdType="pubmed">37344737</ArticleId><ArticleId IdType="pmc">10692252</ArticleId></ArticleIdList></Reference><Reference><Citation>Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, Shamseer L, Tetzlaff JM, Akl EA, Brennan SE, Chou R, Glanville J, Grimshaw JM, Hr&#xf3;bjartsson A, Lalu MM, Li T, Loder EW, Mayo-Wilson E, McDonald S, McGuinness LA, Stewart LA, Thomas J, Tricco AC, Welch VA, Whiting P, Moher D. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372: n7.</Citation></Reference><Reference><Citation>Wells GA, Tugwell P, O&#x2019;Connell D, Welch V, Peterson J, Shea B, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomized studies in meta-analyses 2015.</Citation></Reference><Reference><Citation>Sterne JAC, Savovi&#x107; J, Page MJ, Elbers RG, Blencowe NS, Boutron I, Cates CJ, Cheng HY, Corbett MS, Eldridge SM, Emberson JR, Hern&#xe1;n MA, Hopewell S, Hr&#xf3;bjartsson A, Junqueira DR, J&#xfc;ni P, Kirkham JJ, Lasserson T, Li T, McAleenan A, Reeves BC, Shepperd S, Shrier I, Stewart LA, Tilling K, White IR, Whiting PF, Higgins JPT. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366: l4898.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.l4898</ArticleId><ArticleId IdType="pubmed">31462531</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie Y,&#xa0;Choi T,&#xa0;Al-Aly Z. Nirmatrelvir and the Risk of Post-Acute Sequelae of COVID-19. medRxiv&#xa0;2022.11.03.22281783;&#xa0; https://doi.org/10.1101/2022.11.03.22281783</Citation></Reference><Reference><Citation>Boglione L, Meli G, Poletti F, Rostagno R, Moglia R, Cantone M, Esposito M, Scianguetta C, Domenicale B, Di Pasquale F, Borr&#xe8; S. Risk factors and incidence of long-COVID syndrome in hospitalized patients: does remdesivir have a protective effect? QJM. 2022;114:865&#x2013;71.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/qjmed/hcab297</ArticleId><ArticleId IdType="pubmed">34850210</ArticleId></ArticleIdList></Reference><Reference><Citation>Badenes Bonet D, Caguana V&#xe9;lez OA, Duran Jord&#xe0; X, et al. Treatment of COVID-19 during the acute phase in hospitalized patients decreases post-acute sequelae of COVID-19. J Clin Med. 2023;12:4158.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm12124158</ArticleId><ArticleId IdType="pubmed">37373850</ArticleId><ArticleId IdType="pmc">10299438</ArticleId></ArticleIdList></Reference><Reference><Citation>Nevalainen OPO, Horstia S, Laakkonen S, et al. Effect of remdesivir post hospitalization for COVID-19 infection from the randomized SOLIDARITY Finland trial. Nat Commun. 2022;13:6152.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-022-33825-5</ArticleId><ArticleId IdType="pubmed">36257950</ArticleId><ArticleId IdType="pmc">9579198</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie Y, Choi T, Al-Aly Z. Association of treatment with nirmatrelvir and the risk of post-COVID-19 condition. JAMA Intern Med. 2023;183:554&#x2013;64.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamainternmed.2023.0743</ArticleId><ArticleId IdType="pubmed">36951829</ArticleId><ArticleId IdType="pmc">10037200</ArticleId></ArticleIdList></Reference><Reference><Citation>Chuang MH, Wu JY, Liu TH, Hsu WH, Tsai YW, Huang PY, Lai CC. Efficacy of nirmatrelvir and ritonavir for post-acute COVID-19 sequelae beyond 3 months of SARS-CoV-2 infection. J Med Virol. 2023;95: e28750.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.28750</ArticleId><ArticleId IdType="pubmed">37185834</ArticleId></ArticleIdList></Reference><Reference><Citation>Bramante CT, Buse JB, Liebovitz DM, et al. Outpatient treatment of COVID-19 and incidence of post-COVID-19 condition over 10 months (COVID-OUT): a multicentre, randomised, quadruple-blind, parallel-group, phase 3 trial. Lancet Infect Dis. 2023;S1473&#x2013;3099:00299&#x2013;302.</Citation></Reference><Reference><Citation>Milne A,&#xa0;Maskell S,&#xa0;Sharp C,&#xa0;Hamilton FW,&#xa0;Arnold DT. Impact of dexamethasone on persistent symptoms of COVID-19: an observational study. medRxiv;&#xa0;doi:&#xa0; https://doi.org/10.1101/2021.11.17.21266392</Citation></Reference><Reference><Citation>National Institute for Health and Care Excellence (NICE), Royal College of General Practitioners, Healthcare Improvement Scotland SIGN. COVID-19 rapid guideline: managing the long-term effects of COVID-19. London: National institute for health and care excellence, 2020. www.nice.org.uk/ guidance/ng188 (accessed Oct 30, 2022).</Citation></Reference><Reference><Citation>Singh RSP, Toussi SS, Hackman F, Chan PL, Rao R, Allen R, Van Eyck L, Pawlak S, Kadar EP, Clark F, Shi H, Anderson AS, Binks M, Menon S, Nucci G, Bergman A. Innovative Randomized phase i study and dosing regimen selection to accelerate and inform pivotal COVID-19 trial of Nirmatrelvir. Clin Pharmacol Ther. 2022;112:101&#x2013;11.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cpt.2603</ArticleId><ArticleId IdType="pubmed">35388471</ArticleId></ArticleIdList></Reference><Reference><Citation>Paxlovid EU. Accessed 15 July 2023. Available from: https://aspr.hhs.gov/COVID-19/Therapeutics/Products/Paxlovid Pages/emergency-use-authorization.aspx</Citation></Reference><Reference><Citation>Malin JJ, Su&#xe1;rez I, Priesner V, F&#xe4;tkenheuer G, Rybniker J. Remdesivir against COVID-19 and other viral diseases. Clin Microbiol Rev. 2021;34:e00162-e220.</Citation></Reference><Reference><Citation>RECOVERY Collaborative Group, Horby P, Lim WS, Emberson JR, Mafham M, Bell JL, Linsell L, Staplin N, Brightling C, Ustianowski A, Elmahi E, Prudon B, Green C, Felton T, Chadwick D, Rege K, Fegan C, Chappell LC, Faust SN, Jaki T, Jeffery K, Montgomery A, Rowan K, Juszczak E, Baillie JK, Haynes R, Landray MJ. Dexamethasone&#xa0;in hospitalized patients with&#xa0;COVID-19. N Engl J Med. 2021;384:693&#x2013;704.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2021436</ArticleId></ArticleIdList></Reference><Reference><Citation>Lv Z, Guo Y. Metformin and its benefits for various diseases. Front Endocrinol. 2020;11:191.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fendo.2020.00191</ArticleId></ArticleIdList></Reference><Reference><Citation>Fern&#xe1;ndez-de-las-Pe&#xf1;as C, Rodr&#xed;guez-Jim&#xe9;nez J, Cancela-Cilleruelo I, Guerrero-Peral A, Mart&#xed;n-Guerrero JD, Garc&#xed;a-Azor&#xed;n D, Cornejo-Mazzuchelli A, Hern&#xe1;ndez-Barrera V, Pellicer-Valero OJ. Post-COVID-19 symptoms 2 years after SARS-CoV-2 infection among hospitalized vs non-hospitalized patients. JAMA Netw Open. 2022;5: e2242106.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2022.42106</ArticleId><ArticleId IdType="pubmed">36378309</ArticleId><ArticleId IdType="pmc">9667330</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuri-Ayache M, Rivera-Cavazos A, P&#xe9;rez-Castillo MF, Santos-Mac&#xed;as JE, Gonz&#xe1;lez-Cant&#xfa; A, Luviano-Garc&#xed;a JA, Jaime-Villal&#xf3;n D, Gutierrez-Gonz&#xe1;lez D, Romero-Ibarguengoitia ME. Viral load and its relationship with the inflammatory response and clinical outcomes in hospitalization of patients with COVID-19. Front Immunol. 2023;13:1060840.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2022.1060840</ArticleId><ArticleId IdType="pubmed">36685564</ArticleId><ArticleId IdType="pmc">9845766</ArticleId></ArticleIdList></Reference><Reference><Citation>Su Y, Yuan D, Chen DG, et al. Multiple early factors anticipate post-acute COVID-19 sequelae. Cell. 2022;185:881&#x2013;95.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2022.01.014</ArticleId><ArticleId IdType="pubmed">35216672</ArticleId><ArticleId IdType="pmc">8786632</ArticleId></ArticleIdList></Reference><Reference><Citation>Bramante CT, Huling JD, Tignanelli CJ, et al. Randomized trial of metformin, ivermectin, and fluvoxamine for COVID-19. N Engl J Med. 2022;387:599&#x2013;610.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2201662</ArticleId><ArticleId IdType="pubmed">36070710</ArticleId><ArticleId IdType="pmc">9945922</ArticleId></ArticleIdList></Reference><Reference><Citation>Mulchandani R, Lyngdoh T, Kakkar AK. Deciphering the COVID-19 cytokine storm: systematic review and meta-analysis. Eur J Clin Invest. 2021;51: e13429.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/eci.13429</ArticleId><ArticleId IdType="pubmed">33058143</ArticleId></ArticleIdList></Reference><Reference><Citation>Coomes EA, Haghbayan H. Interleukin-6 in COVID-19: a systematic review and meta-analysis. Rev Med Virol. 2020;30:1&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/rmv.2141</ArticleId><ArticleId IdType="pubmed">32845568</ArticleId></ArticleIdList></Reference><Reference><Citation>Castle BT, Dock C, Hemmat M, Kline S, Tignanelli C,&#xa0;Rajasingham R, Masopust D, Provenzano P,&#xa0;Langlois R,&#xa0;Schacker T,&#xa0;Haase A,&#xa0;Odde DJ. Biophysical modeling of the SARS-CoV-2 viral cycle reveals ideal antiviral targets. bioRxiv&#xa0;2020.05.22.111237</Citation></Reference><Reference><Citation>Tran VT, Riveros C, Clepier B, et al. Development and validation of the long COVID symptom and impact tools, a set of patient-reported instruments constructed from patients&#x2019; lived experience. Clin Infect Dis. 2022;74:278&#x2013;87.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciab352</ArticleId><ArticleId IdType="pubmed">33912905</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>